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Abstract
Background: Human glutamic acid decarboxylase 65 (hGAD65) is a key autoantigen in type 1
diabetes, having much potential as an important marker for the prediction and diagnosis of type 1
diabetes, and for the development of novel antigen-specific therapies for the treatment of type 1
diabetes. However, recombinant production of hGAD65 using conventional bacterial or
mammalian cell culture-based expression systems or nuclear transformed plants is limited by low
yield and low efficiency. Chloroplast transformation of the unicellular eukaryotic alga
Chlamydomonas reinhardtii may offer a potential solution.
Results: A DNA cassette encoding full-length hGAD65, under the control of the C. reinhardtii
chloroplast  rbcL promoter and 5'- and 3'-UTRs, was constructed and introduced into the
chloroplast genome of C. reinhardtii by particle bombardment. Integration of hGAD65 DNA into the
algal chloroplast genome was confirmed by PCR. Transcriptional expression of hGAD65  was
demonstrated by RT-PCR. Immunoblotting verified the expression and accumulation of the
recombinant protein. The antigenicity of algal-derived hGAD65 was demonstrated with its
immunoreactivity to diabetic sera by ELISA and by its ability to induce proliferation of spleen cells
from NOD mice. Recombinant hGAD65 accumulated in transgenic algae, accounts for
approximately 0.25–0.3% of its total soluble protein.
Conclusion: Our results demonstrate the potential value of C. reinhardtii chloroplasts as a novel
platform for rapid mass production of immunologically active hGAD65. This demonstration opens
the future possibility for using algal chloroplasts as novel bioreactors for the production of many
other biologically active mammalian therapeutic proteins.
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Background
In recent years, there has been increased interest in using
genetically engineered plants as an alternative expression
system for the production of recombinant pharmaceutical
proteins [1,2]. Plant systems offer advantages over con-
ventional expression platforms in a number of areas,
including low production cost, easy and quick scale-up,
low risk of product contamination by mammalian viruses
or blood-borne pathogens, and an overall higher quality
of products. To date, nuclear transformed plants have
been shown to be able to produce numerous recombinant
proteins of therapeutic value, including human diagnostic
and therapeutic full-length and single-chain antibodies,
antigens, cytokines and autoantigens. Moreover, crop
plants can be used for the production and delivery of safe
and effective edible vaccines against various infectious
and immune-related diseases (For more information, see
recent reviews by Ma et al. [3,4]. Despite this promise,
nuclear transformed transgenic plants often yield rela-
tively low levels of recombinant protein. For example, the
nuclear expression of hepatitis B virus (HBV) envelop sur-
face protein in transgenic tobacco plants was reported as
0.01% of total soluble protein (TSP) [5], whereas the
accumulation level of cholera toxin B subunit (CTB), a
vaccine antigen against cholera, in nuclear transgenic
tobacco was between 0.02 to 0.1% of TSP [6,7]. Therefore,
new strategies need to be developed to overcome limited
recombinant protein accumulation before the potential of
transgenic plants for therapeutic protein production can
be fully realized.
An alternative strategy for improving foreign protein pro-
duction yield is through chloroplast transformation of
higher plants or closely related eukaryotic green algae. Evi-
dence suggests that use of transgenic chloroplasts as bio-
reactors offers significant advantages over nuclear
transformed plants. These include high-level protein accu-
mulation due to increased foreign gene content in chloro-
plasts (up to 10,000 copies/leaf cell in tobacco; or 80
copies/cell in Chlamydomonas reinhardtii), expression of
multiple genes through a single transformation event,
increased transgene containment because of maternal
plastid inheritance, as well as a lack of position effects on
foreign genes [8]. Additionally, the endogenous presence
of chloroplast chaperones and enzymes aids in complex
multi-subunit protein assembly and can correctly fold
proteins containing disulfide bonds, thereby drastically
reducing the costs of in vitro processing. High levels of for-
eign proteins have been obtained via expression through
the chloroplast genome. For example, the expression level
of CTB in chloroplast transgenic plants reached up to
4.1% of TSP [9], while its expression level in nuclear trans-
genic plants accounted for 0.02 to 0.1% of TSP [6,7]. Sim-
ilarly, while the expression level of human serum
albumin, an important therapeutic protein with many
applications, in nuclear transgenic plants was around
0.2% of TSP [10], expression levels of up to 11.2% of TSP
were observed in chloroplast transgenic plants [11]. There
are many other vaccine antigens or biopharmaceutical
proteins that have been produced in chloroplast trans-
genic plants. They include, for example, Bacillus anthracis
protective antigen (PA) against anthrax [12,13], fragment
C of tetanus toxin (TetC) for tetanus [14], the outer sur-
face protein A (OspA) of Borrelia burgdorferi against Lyme
disease [15] and cytokines such as interferonα2b
(IFNα2b) and IFN-γ [16,17] as well as a diabetes-associ-
ated autoantigen human proinsulin [18]. Furthermore,
many of them have been shown to be fully functional in
animal studies. The reader is referred to the recent reviews
by Daniell and colleagues for further information
[8,19,20].
Compared to chloroplast transgenic plants, the use of
chloroplast transgenic algae as a bioreactor offers several
additional advantages. Microalgae, such as C. reinhardtii,
grow and reproduce faster than any other terrestrial or
aquatic plant, doubling its biomass in approximately 8
hour, and microalgae are non-toxic and non-polluting,
thus environmentally friendly for mass cultivation and
commercial exploitation. Also, there will be a significant
reduction in the time required to generate transgenic algae
as compared to higher plants. In general, stable transplas-
tomic lines can be obtained in as little as 3 weeks, with the
potential to scale up to mass production in an additional
4–6 weeks [21]. All of these have made microalgal chloro-
plasts to be another valuable platform for the molecular
farming of pharmaceutical proteins. Indeed, the C. rein-
hardtii chloroplast expression of a large single-chain anti-
body has shown accumulation levels of 0.5 to 1% of algal
TSP [22]. Recently, Manuell et al. [23] demonstrated
robust expression of a bioactive mammalian peptide,
bovine mammary-associated serum amyloid (M-SAA), in
C. reinhardtii chloroplasts with levels up to 5% of TSP.
There are several other antigenic proteins that have been
produced using this system, including foot-and-mouth
disease virus VP1 protein [24], tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) [25] and the
protein E2 of classical swine fever virus [26]. The reader is
referred to recent reviews on this area for further informa-
tion [21,27].
Glutamic acid decarboxylase-65 (GAD65) catalyzes the
formation of gamma-aminobutyric acid (GABA) from
glutamine. It is one of the major autoantigens in type 1
(insulin-dependent) diabetes, an autoimmune disease
resulting from the destruction of insulin-producing β cells
in the pancreas [28,29]. It has been demonstrated that
many new-onset type 1 diabetic patients have autoanti-
bodies against GAD65, with the presence of anti-GAD65
antibodies now serving as an important marker for theBMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
Page 3 of 13
(page number not for citation purposes)
prediction and diagnosis of type 1 diabetes [30-32]. The
identification of GAD as a major autoantigen in type 1
diabetes may also present unique opportunities for the
development of novel preventative therapies against the
disease. Indeed, immunization of young non-obese dia-
betic (NOD) mice, an animal model for human type 1
diabetes, with GAD65 or GAD peptides prevents or delays
the onset of diabetes [33-35]. Furthermore, the suppres-
sion of GAD in NOD mouse islets was shown to protect
the mice from developing diabetes [36]. All of these
results suggest the potential importance of GAD65 in
diagnosing and treating type 1 diabetes in humans. How-
ever, recombinant production of hGAD65 using conven-
tional bacterial or mammalian cell culture-based
expression systems is limited by high cost, low efficiency
and low yield. To overcome these limitations, we have
recently explored transgenic plants as an alternative
expression platform for the production of hGAD65 [37].
Although transgenic plants offer several production
advantages, including the possibility of allowing direct
oral delivery of plant-derived GAD65 to induce oral
immune tolerance, plant expression of hGAD65 is still
limited by low accumulation levels (0.04% of TSP in
tobacco).
The goal of the present study was to investigate the feasi-
bility of using C. reinhardtii chloroplasts as a novel expres-
sion platform for the production of hGAD65. To this end,
a chloroplast transformation vector containing the full-
length hGAD65 gene, under the control of the C. rein-
hardtii chloroplast rbcL promoter as well as rbcL 5'- and 3'-
UTRs, was generated and introduced into the chloroplast
genome of C. reinhardtii. Here, we show that chloroplast
transformed C. reinhardtii  cells express and accumulate
recombinant hGAD65 at levels of 0.25–0.3 % of algal
TSP. Immunological analysis shows algal-derived recom-
binant hGAD65 reacts with Type 1 diabetic sera from
NOD mice, and stimulates the proliferation of spleen
lymphocytes from NOD mice. These results demonstrate
that agal-derived GAD65 contains its authentic antigenic-
ity, further suggesting the potential use for microalgae as
a novel production system for human therapeutic pro-
teins.
Methods
Strains, growth media and culture conditions
C. reinhardtii wild-type strain 137c was used as a host for
chloroplast transformation. Cells of the strain 137c were
maintained on Tris Acetate Phosphate (TAP) agar or
grown in liquid TAP medium at 23°C under constant illu-
mination of ~100 μE/m2·sec-1. When grown in TAP liquid
medium, algal cells were cultured in flasks rotating at 100
rpm.
Construction of the chloroplast expression vector pXW-
GAD-His
To construct chloroplast expression vector pXW-GAD65-6
× His, hGAD65 cDNA was amplified by PCR from plasmid
vector pTRL-GAD65 [37] using the primer pairs: 5'- TTC-
CATGGCATCTCCGGGCTCTGGC-3' (forward) and 5'-
ATAATCTAGATTAATGATGATGATGATGATGTAAATCTT-
GTCCAAGGCG TTC-3' (reverse). The forward primer con-
tains an engineered NcoI site (underlined), whereas the
reverse primer contains an XbaI site (underlined) immedi-
ately downstream of sequence encoding the 6 × His-tag
(italic) and stop codon (bold). PCR was performed on a
Perkin-Elmer Model 9600 thermocycler under the follow-
ing conditions: initial denaturation for 5 min at 94°C, fol-
lowed by 30 cycles of denaturation at 94°C for 30 s,
annealing at 50°C for 30 s, and extension at 72°C for 60
s, followed by a final extension of 10 min at 72°C. The
PCR product was isolated and blunt-end ligated into the
SmaI site of pUC19. After verification by sequence analy-
sis, the hGAD65 gene was released by digestion with NcoI
and XbaI, blunt-ended with Klenow fragment, and cloned
into  Chlamydomonas  chloroplast transformation vector
pUC7-463, composed of the rbcL gene promoter and its 5'
untranslated region (5' UTR) and 3' UTR. The resulting
hGAD65 expression cassette was then isolated as a single
BamHI fragment and ligated into the C. reinhardtii chloro-
plast transformation vector p322, containing the 5.7 kb
EcoRI/XhoI restriction fragment from the C. reinhardtii
inverted repeat region (Chlamydomonas Stock Center),
forming plasmid pXW-GAD-His.
Chloroplast tranformation
C. reinhardtii wild type strain 137c was grown in TAP liq-
uid medium to late log phase (approximately 7 days),
with subsequent cell harvesting by centrifugation (2060 g
for 10 minutes at 4°C). The cell pellet was resuspended in
TAP to a density of approximately 1.0 × 108 cells/mL. Of
this cell suspension, 250 μl was spotted onto the central
area (1.5 cm in diameter) of a TAP agar plate and incu-
bated in the dark at room temperature for 2 hours. After
incubation, plates were bombarded with 5 μg of pXW-
GAD-His DNA mixed with equal amounts of plasmid
p228 DNA and coated onto tungsten particles for delivery
using a Biolistic PDS-1000/He Particle Delivery System
(Bio-Rad Laboratories) as described by Boynton et al.
[38]. Plasmid p228, containing the 16S rRNA gene confer-
ring spectinomycin resistance, was used to screen and/or
identify transformed algal cells. Bombarded cells were
incubated overnight in the dark at room temperature, re-
plated onto TAP agar plates containing spectinomycin
(150 μg/mL) and incubated under dim light. Colonies
appearing after 2–3 weeks were re-streaked onto TAP agar
plates containing spectinomycin and grown for approxi-
mately one more week. Colony cells were subcultured
into TAP liquid medium containing 50 μg/ml spectino-BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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mycin and grown for one day under shaking conditions.
Cells were then diluted and plated onto TAP agar plates
containing spectinomycin to obtain single colonies. Sev-
eral rounds of replating on selective medium were
required to obtain homoplasmic cell lines.
DNA isolation and PCR analysis
Total DNA was isolated from wild-type C. reinhardtii and
transformants using the method described by Newman et
al. [39] with minor modifications. Briefly, cells were
grown in liquid TAP medium, harvested by centrifugation
(2000 × g for 10 min at 4°C) and resuspended in TEN
buffer (10 mM Tris-HCl, 10 mM EDTA, 150 mM NaCl, pH
8.0). The cell suspension was centrifuged, and the pellet
resuspended in 150 μl H2O on ice and to it, 300 μl of SDS-
EB buffer (2% SDS, 400 mM NaCl, 40 mM EDTA, 100
mM Tris-HCl, pH 8.0) was added. The suspension was
extracted once with 350 μl of phenol/CIA (25:24:1 by vol-
ume, phenol:chloroform:isoamyl alcohol) and the aque-
ous phase was collected and added with 300 μl of CIA.
After a final centrifugation, the aqueous phase was col-
lected, mixed with two volumes of 100% ethanol and
incubated on ice for 30 minutes. The solution was centri-
fuged at 12,000 × g for 10 minutes to pellet the DNA. The
DNA was then subjected to PCR analysis. To confirm the
presence of the hGAD65 gene, PCR was performed using
the following pair of hGAD65 specific primers: forward 5'-
AAGAATTCTGGCATCTCCGGGCTCTG-3' (GAD-1), and
reverse 5'- AATTCTCGAGTTATAAATCTTGTCCAAGGCG-
3' (GAD-2). PCR reaction conditions were as follows: ini-
tial denaturation at 94°C for 5 min, followed by 35 cycles
of denaturation at 94°C for 1 min, annealing at 50°C for
30 s, and extension at 72°C for 60 s, followed by a final
extension of 10 min at 72°C. To determine the specific
integration site of GAD65 in the chloroplast genome, long
range PCR was performed using the long PCR enzyme mix
(Fermentas, Glen Burnie, MD) with primer sets CP3,
GAD-1 and CP4, GAD-2. The primer CP3 (5'-CCGTTCGT-
GCTGTGCTAGACAG-3') represents a location at one end
of the inverted region of the chloroplast genome in C.
reinhardtii, whereas the primer CP4 (5'-CGAATAACT-
GGGTGAATTGTCAGG-3') represents a location at the
other end of this inverted region (Figure 1). PCR reaction
conditions were as follows: initial denaturation at 94°C
for 2 min, 10 cycles of 20 s each at 94°C, 30 s at 59°C and
4 min at 68°C followed by 25 cycles of 20 s each at 94°C,
30 s at 59°C and 4 min and 2 s at 68°C. To identify homo-
plasmic cell lines, PCR was performed with chloroplast
specific primers CP3 and CP4 using the following reaction
conditions: initial denaturation at 94°C for 5 min, 10
cycles of 20 s each at 94°C, 30 s at 57°C and 7 min at
68°C, and followed by 25 cycles of 20 s each at 94°C, 30
s at 57°C and 7 min and 5 s at 68°C. PCR products were
analysed by agarose gel electrophoresis.
RNA isolation and RT-PCR analysis
Total RNA was extracted from wild-type C. reinhardtii and
transformants using the TRIzol RNA extraction kit accord-
ing to the manufacturer's instructions. RNA was reverse
transcribed to cDNA by SuperScript II Reverse Tran-
scriptase (Invitrogen) according to the manufacturer's
protocol. Briefly, 5 μg of total RNA, 1 μl Oligo(dT)12–18
(500 μg/ml), 1 μl dNTP Mix (10 mM each) and 5 μl sterile
distilled water were mixed and incubated at 65°C for 5
min. Following addition of 4 μl First-Strand Buffer and 2
μl 0.1 M DTT, the reaction mixture was further incubated
for 2 min at 42°C. After incubation, 1 μl of SuperScript™
II Reverse Transcriptase was added and incubated at 42°C
for 50 min. The resulting cDNA was used as template for
PCR, using hGAD65 specific primers. PCR reactions con-
tained 2 μl of cDNA, 0.2 mM dNTPs, 2 μM of each primer,
1× reaction buffer, 1.5 mM MgCl2, and 2.5 U of Taq
polymerase in a total volume of 50 μl. These reactions
were incubated at 95°C for 5 min, followed by 30 cycles
of 94°C for 1 min, 50°C for 1 min, 72°C for 2 min with
a final extension of 10 min at 72°C. The PCR products
were ran on a 1.5% agarose gel and compared against a
DNA ladder (Life Technologies, Grand Island, NY).
Western Blot analysis
Total crude protein was extracted from transformants and
wild-type C. reinhardtii using the method as described by
Goldschmidt-Clermont [40]. For immunoblot analysis,
protein extract was boiled, separated on a 15% SDS poly-
acrylamide gel and blotted onto PVDF (polyvinylidene
difluoride) membrane (Millipore, Burlington, MA).
Membranes were blocked in 5% skim milk-TBST(20 mM
Tris, 150 mM NaCl, 0.02% Tween 20, pH 7.6), washed
with TBST, and then incubated for 1 h with a 1:2000 dilu-
tion of a rabbit anti-GAD65/67 primary antibody (Sigma-
Aldrich Canada, Oakville, Ontario) followed by incuba-
tion with 1:2500 diluted horseradish peroxidase conju-
gated goat anti-rabbit secondary antibody.
Immunodetection was performed using the enhanced
chemiluminescence (ECL) detection system (Perkin
Elmer Life Sciences, Rockford, IL) according to the manu-
facturer's instructions. Quantification of the expression
level of hGAD65 in algal cells was performed by a sand-
wich ELISA. In brief, a 96-well microtiter plate was coated
with mouse anti-GAD65 (Abcam, Cambridge, MA) anti-
body at a concentration of 0.2 μg/well, and incubated at
4°C overnight. The wells were washed three times with
PBST (phosphate saline containing 0.05% Tween-20),
and blocked with 3% BSA in PBS for 2 hours at room tem-
perature. After washing three times with PBST, 1 μg of
extracted total algal protein was added per well, and plates
incubated overnight at 4°C. After washing with PBST, 0.2
μg of rabbit anti-GAD65 (Serotec, Hornby, Canada) was
added per well and incubated at room temperature for 2
hours. After washing, 50 μL of 1:2000 diluted HRP-conju-BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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gated anti-rabbit IgG antibody (Kirkegaard & Perry Labo-
ratories, Gaithersburg, USA) was added per well and
incubated at 37°C for 1 hour. After incubation, 100 μL/
well of TMB substrate (R&D Systems, Minneapolis, MN)
was added and incubated at 37°C for 15 minutes for color
development. The color reaction was stopped by addition
of 100 μL/well stop solution (R&D Systems, Minneapolis,
MN). The plate was read in a microplate reader (Bio-Rad
3550) at 450 nm. The hGAD65 concentration in samples
was determined by comparison to a standard curve cre-
ated with purified hGAD65 standard (Diamyd Diagnos-
tics, Sweden).
Purification of algal-derived hGAD65 protein
Algal-derived recombinant hGAD65 was purified by histi-
dine affinity chromatography using HiTrap Chelating HP
columns (GE Healthcare) according to the manufacturer's
instructions. In brief, a total of 100 ml of C. reinhardtii
cells were homogenized in 1 ml extraction buffer (750
mM Tris-HCl, pH 8.0; 15% sucrose; 100 mM β-mercap-
toenthanol; 1 mM PMSF). The homogenate was centri-
fuged at 13,000 × g for 20 min at 4°C. The supernatant
was filtered through a 0.45 μm membrane filter, and
loaded onto a HiTrap Chelating HP column and washed
with wash buffer (10 mM imidazol, 20 mM Na2HPO4,
500 mM NaCl) to remove nonspecifically bound endog-
enous algal proteins. The bound algal-derived hGAD65
was eluted with elution buffer (500 mM imidazol, 20 mM
Na2HPO4, 500 mM NaCl). Fractions were collected and
analysed by SDS-PAGE and ELISA. The hGAD65 fraction
was then dialyzed extensively against PBS to remove high
salt and imidazolel, and concentrated using a speed vac-
uum.
Schematic diagram of the hGAD65 chloroplast expression vector pXW-GAD-His and the site of integration of the transgene  cassette into the chloroplast genome Figure 1
Schematic diagram of the hGAD65 chloroplast expression vector pXW-GAD-His and the site of integration of 
the transgene cassette into the chloroplast genome. The hGAD65 expression cassette consists of the C. reinhardtii chlo-
roplast rbcL promoter and 5'UTR upstream of the transgene followed by the rbcL 3'UTR. The transgene cassette was inserted 
into plasmid vector p322 that contains a cloned 5.7 kb (EcoRI/XhoI fragment) inverted repeat of C. reinhardtii chloroplast DNA, 
resulting in pXW-GAD-His. The restriction sites used for cloning are indicated. Primers GAD-1/GAD-2 corresponding to the 
5' and 3' ends of hGAD65 were used for PCR analysis to confirm the presence of the transgene in transformants, with the 
expected product size indicated. Primers CP3/CP4 complementary to sequences lying just outside the inverted repeat region 
of the C. reinhardtii chloroplast DNA were used to determine the site-specific integration of the transgene cassette into the C. 
reinhardtii chloroplast genome by PCR. The site-specific integration of the transgene cassette was additionally determined by 
PCR using GAD-1/CP3 and CP4/GAD-2 primer pairs. The regions for homologous recombination are indicated by the crosses. 
Selection of C. reinhardtii transformants was based on resistance to spectinomycin that was provided by co-transformation with 
plasmid p228 that contains the 16S rRNA gene conferring spectinomycin resistance [38].BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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Determination of immunoreactivity of algal-derived 
hGAD65 with diabetic sera by ELISA
The antigenicity of algal-derived hGAD65 was determined
by its immunoreactivity with diabetic sera from NOD
mice using ELISA. In brief, purified algal-derived recom-
binant hGAD65 was added to a 96-well microtiter plate in
a volume of 50 μl/well (10 μg GAD65/ml diluted in 0.1 M
NaHCO3, pH 8.5) and incubated overnight at 4°C. After
incubation, the plate was washed, blocked with 3% BSA
in PBS solution, and incubated overnight at 4°C with dia-
betic and control serum samples (50 μl/well in triplicate).
Diabetic serum samples were obtained from newly-onset
diabetic NOD mice, whereas control serum samples were
collected from BALB/c mice. After washing, 50 μL of
1:2000 diluted HRP-conjugated anti-mouse IgG antibody
was added per well and the plate incubated at 37°C for 2
hours. The color development was performed as described
above for sandwich ELISA.
Spleen cell proliferation assay
For the spleen cell proliferation assay, spleen cell suspen-
sions were prepared from 8-week-old NOD mice. In brief,
individual spleens were pressed through a sterile Falcon
cell strainer (Becton Dickinson, Franklin Lakes, NJ), and
lysed with ammonium chloride potassium (ACK) lysis
buffer (Gibco/BRL, Rockville, MD) to remove erythro-
cytes. The resulting cell suspension was washed with
DPBS (Dulbecco's phosphate buffered saline, Sigma-
Aldrich Canada, Oakville, Ontario), and resuspended in
complete RPMI 1640 media at a viable cell concentration
of 5 × 105 ml-1. Spleen cells were plated in triplicate in 96-
well flat-bottom microtitre plates (100 μl/well), with
insect cell-derived hGAD65 standard (Diamyd Diagnos-
tics, Sweden), algal-derived hGAD65 or the unrelated pro-
tein antigen ovalbumin (OVA) (100 μl/well of 10 μg/ml
hGAD65 or OVA) added. The cell cultures were incubated
at 37°C in a 5% CO2-humidified incubator for 72 hours
and pulsed with 1 μCi/well tritiated thymidine. After a 16
hour post growth, cells were harvested, and the tritiated
thymidine incorporated was determined by using a Beck-
man LS 6500 liquid scintillation counter (Beckman Coul-
ter, Fullerton, Califonia). Results were shown as the mean
counts per minute (CPM) of triplicate spleen-cell cultures.
Results
Construction of a chloroplast expression vector and algal 
transformation
The plasmid pXW-GAD-His (Figure 1) was constructed
and used for C. reinhardtii chloroplast transformation. The
expression of hGAD65 was under the control of the C.
reinhardtii chloroplast rbcL promoter and 5' UTR and 3'
UTR. A C-terminal 6 × His tag was added to facilitate puri-
fication of the recombinant protein using metal-affinity
chromatography. The chimeric gene was flanked by
sequence from an inverted repeat region of the C. rein-
hardtii  chloroplast genome to provide sites for in vivo
homologous recombination. The plasmid pXW-GAD-His
was transformed into wild-type C. reinhardtii chloroplasts
by particle bombardment along with the plasmid p228
conferring spectinomycin resistance as a means of selec-
tion.
PCR analysis of C. reinhardtii transformants
C. reinhardtii transformants were selected on TAP agar
plates supplemented with spectinomycin (TAP-Spec). Pri-
mary putative transformants were initially screened by
PCR for the presence of the hGAD65 gene using GAD spe-
cific primers. As shown in Figure 2A, PCR amplification of
the genomic DNA obtained from primary transformants
resulted in the synthesis of a product with expected 1.65
kb size. No PCR products were produced from DNA iso-
lated from wild-type C. reinhardtii. Positive transformants
were administered additional rounds of selection in order
to obtain homoplasmic cell lines in which all copies of
the chloroplast genome contained the introduced chi-
meric hGAD65 gene. To demonstrate that the hGAD65
expression cassette was site-specifically integrated into the
algal chloroplast genome, long PCR amplification of
genomic DNA from selected transformants was per-
formed using a combination of primer sets. As indicated
in Figure 1, primers CP3 and CP4 were designed to be
complementary to sequences lying just outside the
inverted repeat region of the C. reinhardtii chloroplast,
and therefore PCR amplification of genomic DNA from
transformants with a CP3 and CP4 primer pair would give
an expected 8.4 kb DNA product if the hGAD65 cassette
was correctly inserted into the inverted region of the algal
chloroplast genome. As shown in Figure 2B, a DNA frag-
ment of expected size was produced after PCR amplifica-
tion. In contrast, PCR amplification of genomic DNA
from wild-type C. reinhardtii using the same CP3/CP4
primer pair produced a band of smaller molecular weight
(5.8 kb), equivalent in size to the inverted repeat region of
the algal chloroplast DNA lacking inserted foreign DNA.
The apparent lack of amplification of any 5.8 kb product
from the inverted repeat region of chloroplast DNA with
transformants further implies that transformants are all
homoplasmic. Additional long PCR was performed using
a combination of GAD and chloroplast specific primers to
show foreign DNA inserted to the chloroplast inverted
region was indeed that of hGAD65. The primer GAD-1
was designed according to the N-terminal coding
sequence of hGAD65. When CP3 and GAD-1 were used as
a primer pair, a 4-kb PCR product spanning the full
hGAD65 coding sequence (1.65 kb), 3' rbcL UTR (440 bp)
and the XhoI-BamHI fragment (2 kb) of the flanking
inverted repeat region would be expected. As shown in
Figure 2C, a 4-kb DNA fragment was obtained with the
use of this primer pair. Similarly, when GAD-2 (designed
for the C-terminal coding sequence of hGAD65) and CP4BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
Page 7 of 13
(page number not for citation purposes)
PCR analysis of C. reinhardtii transformants Figure 2
PCR analysis of C. reinhardtii transformants. (A) hGAD65 specific primers GAD-1 and GAD-2 generated PCR products 
using total algal DNA as template. Lanes 1 to 5, independent C. reinhardtii transformants; PC, positive control (hGAD65 contain-
ing plasmid pXW-GAD-His). C. reinhardtii wild-type strain 137c DNA was used as a negative control. PCR products are indi-
cated by the arrow. (B) Chloroplast specific primers CP3 and CP4 generated PCR products using total algal DNA as a 
template. Lanes 1 to 2, representative C. reinhardtii transformants; C. reinhardtii wild-type strain 137c DNA was used as a nega-
tive control. PCR products are indicated by the arrows. (C) The CP3/GAD-1 or CP4/GAD-2 primer set generated PCR prod-
ucts. Lane 1, representative C. reinhardtii transformant. C. reinhardtii wild-type strain 137c DNA was used as a negative control. 
PCR products are indicated by the arrows.BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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were used as a primer pair, an expected 5.6-kb PCR prod-
uct (corresponding to the full hGAD65 coding sequence
(1.65 kb), chloroplast rbcL promoter and 5' UTR (390 bp)
and a 3.7-kb BamHI-EcoRI fragment of the flanking
inverted repeat region) was amplified from the same
transformant (Figure 2C). As expected, no PCR products
were generated from C. reinhardtii wild-type strain 137c
DNA when the same CP3 and GAD-1 or CP4 and GAD-2
primer pair was used (Figure 2C). Taken together, these
results suggest all transformants analysed were homoplas-
mic for the hGAD65 cassette site-specifically inserted into
the host chloroplast genome.
Transcriptional analysis of hGAD65 in C. reinhardtii 
transformants by RT-PCR
The transcriptional expression of hGAD65 in C. reinhardtii
transformants was evaluated by RT-PCR from total RNA
isolated from wild-type C. reinhardtii and transformants.
When hGAD65 specific primers were used, a product of
expected size (1.65 kb) was detected in cDNA reverse-
transcribed from RNA isolated from selected transform-
ants (Figure 3). No RT-PCR products were detected in
cDNA from wild-type C. reinhardtii. To rule out possible
amplification of contaminant DNA in the samples, direct
PCR amplification without reverse transcription was per-
formed on the RNA preparations. No amplified PCR
products were seen under the same conditions, confirm-
ing the specificity of the RT-PCR reaction (data not
shown). In summary, these data indicate that hGAD65 is
actively transcribed in chloroplast transformed algal cells.
Accumulation of hGAD65 protein in C. reinhardtii 
transformants
To demonstrate the accumulation of hGAD65 protein,
total soluble protein (TSP) was prepared from wild-type
C. reinhardtii and transformants, and analyzed by Western
blotting.
Anti-human GAD65 polyclonal antibody detected a sin-
gle 65-kDa band, corresponding in size to the hGAD65
protein (Figure 4). No protein band was detected in
extracts from C. reinhardtii wild-type strain 137c. Accumu-
lation levels of hGAD65 in algal cells were measured
using ELISA. As shown in Figure 5, algal derived hGAD65
accounts for up to 0.25 to 0.3% of TSP.
Immunoreactivity of algal-derived hGAD65 with sera from 
diabetic NOD mice
Since prediabetic patients with type 1 diabetes and NOD
mice contain anti-GAD antibodies in their sera [36], the
antigenicity of algal-derived hGAD65 was determined by
its immunoreactivity with diabetic sera. Thus, purified
algal-derived hGAD65 was coated onto a microtiter plate
and tested against three diabetic serum samples collected
from NOD mice. Three serum samples obtained from
BALB/c mice were used as non-diabetic controls. As
shown in Figure 6, all three diabetic serum samples had
higher binding capacity to algal-derived hGAD65 than did
reference serum samples, with samples number 2 and 3
showing a significant difference (p < 0.05). These results
suggest that algal-derived recombinant hGAD65 is anti-
genic.
Effect of algal-derived hGAD65 on spleen cell proliferation
To further assess the antigenicity of algal-derived
hGAD65, the effect of algal-derived hGAD65 on spleen
cell proliferation was analyzed. Splenocytes were isolated
from individual 8-week-old NOD mice and cultured with
medium alone or stimulated with insect cell-derived
hGAD65 standard, algal-derived hGAD65, or the irrele-
vant protein antigen ovalbumin (OVA). As shown in Fig-
RT-PCR detection of hGAD65 mRNA expression in C. reinhardtii transformants Figure 3
RT-PCR detection of hGAD65 mRNA expression in C. reinhardtii transformants. Total RNA was isolated from C. 
reinhardtii wild-type strain 137c and transformants. RNA was transcribed to cDNA as described in Methods. Resulting cDNA 
was amplified using primers specific to hGAD65. Lanes 1 to 4, PCR amplification of cDNA from independent transformants. 
PCR amplification of cDNA from wild-type strain 137c was used as a negative control. PC, positive control (direct PCR ampli-
fication of DNA from plasmid pXW-GAD-His). PCR products are indicated by the arrow.BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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ure 7, NOD mouse-derived spleen cells proliferated
significantly in response to in vitro stimulation with algal-
derived hGAD65, with a magnitude of response compara-
ble to the insect cell-derived hGAD65 standard. In con-
trast, NOD mouse-derived spleen cells cultured with
medium alone or stimulated with OVA showed no signif-
Western blot detection of recombinant hGAD65 from total soluble protein extracted from chloroplast transgenic algal lines Figure 4
Western blot detection of recombinant hGAD65 from total soluble protein extracted from chloroplast trans-
genic algal lines. Samples containing ~50 ng of commercial hGAD65 or 5 μg of total algal protein were separated by 15% 
sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto a polyvinylidene difluoride mem-
brane and probed with rabbit anti-GAD65 primary antibody followed by horseradish peroxidase conjugated goat anti-rabbit 
secondary antibody. Standard, insect cell-derived hGAD65. Lanes 1 to 2, protein extracts from two representative algal trans-
formants. Protein extracts from wild-type strain 137c were used as a negative control. Arrows indicate the position of algal-
derived hGAD65.
Expression levels as percentages of hGAD65 in total soluble protein (TSP) of hGAD65 expressing C. reinhardtii transformants Figure 5
Expression levels as percentages of hGAD65 in total soluble protein (TSP) of hGAD65 expressing C. reinhardtii 
transformants. The expression level was determined by hGAD65 specific ELISA as described in detail in methods. hGAD-1 
and hGAD-2, two independent algal transformants; WT, untransformed wild type C. reinhardtii 137c strain.BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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icant proliferative activity. The difference in cell response
to algal-derived hGAD65 and OVA is significant (p <
0.05). These results provide additional evidence that
algal-derived hGAD65 is indeed immunogenic.
Discussion
The production of recombinant hGAD65 has been
achieved in a number of expression systems including
insect cells and E. coli, but all have been limited by their
efficiency. Only low levels of hGAD65 accumulation was
obtained in baculovirus-infected SF9 insect cells [41].
Moreover, this expression platform is technically and eco-
nomically demanding, and hence is expensive and diffi-
cult to scale-up for mass production. The expression of
hGAD65 as a fusion protein has been demonstrated in E.
coli  [42], but results in accumulation of recombinant
product in insoluble inclusion bodies, needing solubiliza-
tion, renaturation as well as chemical or enzymatic proce-
dures to separate the target protein from its fusion
partners. These additional processes can be expensive and
time consuming. Our recent demonstration that hGAD65
can be expressed in transgenic tobacco may alleviate some
of the problems associated with conventional expression
platforms for hGAD65 production [37]. However, plant
genomic expression of hGAD65 is still limited by low
accumulation levels (0.04% of TSP). Here we report the
use of algal chloroplasts as a new type of bioreactor for the
production of hGAD65. C. reinhardtii transformed with
the hGAD65 gene under control of the chloroplast rbcL
promoter and 5'-UTR was produced. The site-specific inte-
gration of the transgene into the chloroplast genome of C.
reinhardtii was demonstrated by PCR (Figure 2). RT-PCR
analysis revealed viable expression of hGAD65 mRNA in
C. reinhardtii transformants (Figure 3). The accumulation
of recombinant hGAD65 protein was further confirmed
by Western blotting using anti-GAD antibody (Figure 4).
As measured by ELISA, C. reinhardtii derived hGAD65 pro-
tein accounted for up to 0.25 to 0.3% of total algal soluble
protein (TSP) (Figure 5). This value is much higher when
compared to hGAD65 expression in nuclear transgenic
plants (0.04% TSP) [37]. With a significant increase in
immunologically active hGAD65 accumulation, taken
together with C. reinhardtii's rapid growth rate, it is obvi-
ous that microalgae represent a superior platform for
hGAD65 production. In addition, algae are one of the eas-
iest living organisms to propagate, requiring only sun-
Demonstration of immunoreactivity with NOD mouse diabetic sera to algal-derived hGAD65 Figure 6
Demonstration of immunoreactivity with NOD mouse diabetic sera to algal-derived hGAD65. Purified algal-
derived hGAD65 was coated onto 96-well plates and incubated with serum samples from diabetic NOD mice (n = 3) and ref-
erence BALB/c mice (n = 3). Bound anti-GAD antibody was detected with HRP-conjugated anti-mouse IgG. Error bars repre-
sent the standard deviation. ** above bars indicates a significant difference from reference BALB/c sera (p < 0.05).BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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light, carbon dioxyde and water to thrive. It can be easily
grown to industrial levels at very low cost. There are sev-
eral common methods that can be used to grow algae at
large scale, including the use of ponds, cheap flexible plas-
tic bags or a solar photoreactor. As only the unmodified
native form of hGAD65 gene under control of the chloro-
plast rbcL gene promoter and its 5'-UTR was investigated
in this pilot study, it is expected accumulation levels of
hGAD65 in algal cells could be improved further if a C.
reinhardtii  chloroplast codon-optimized version of
hGAD65 gene is used. The native hGAD65 DNA contains
relatively low AT content (52%) and its expression may
not be favored by an AT-rich C. reinhardtii chloroplast
genome in which the overall AT content is 65.5% [43].
Franklin et al. [44] showed an 80-fold increase in expres-
sion levels of GFP (green fluorescent protein) in C. rein-
hardtii  chloroplasts when a synthetic GFP gene with
increased AT content (66% AT content in synthetic GFP in
comparison to native GFP with 60% AT content) was
used. Furthermore, as the 5'-UTR region of chloroplast
mRNAs has a profound effect on the translational effi-
ciency of C. reinhardtii chloroplast genes [45,46], the use
of different 5'-UTRs of chloroplast genes such as the 5'-
UTR of the plastid psbA gene (D1 protein of photosystem
II), combined with a strong promoter, could serve as
another approach to enhance hGAD65 expression in C.
reinhardtii  cells. One additional strategy to improve
hGAD65 expression may be the use of different host
strains of C. reinhardtii. Mayfield and Schultz [47]
reported a much higher expression (10-fold increase) of
the luciferase reporter gene in C. reinhardtii chloroplasts
when it was expressed in a C. reinhardtii mutant strain that
lacked the corresponding endogenous gene (ie, the psbA
deficient strain cc744).
The antigenicity of algal-derived hGAD65 was demon-
strated based on its immunoreactivity with diabetic sera as
well as its ability to stimulate the in vitro proliferation of
splenic T cells derived from NOD mice. Anti-GAD anti-
bodies are present in >70% of newly diagnosed type 1 dia-
betic patients and have been detected up to 7 years before
clinical onset of the disease [48,49]. Measurement of anti-
GAD antibodies has been proposed as a better predictor
for the future development of type 1 diabetes in people at
high risk [50]. Anti-GAD antibodies are also present in the
sera of a majority of NOD mice and can be detected at an
early stage of the disease [33,34]. Our results indicate that
algal-derived hGAD65 reacts specifically with diabetic
sera (Figure 6), suggesting its authentic GAD antigenicity.
The in vitro spleen cell proliferation assay provides further
evidence that algal-derived hGAD65 is immunogenic
(Figure 7). In this assay, spleens derived from 8-week-old
NOD mice were used as a source of spleen cells. In NOD
mice, spontaneous proliferative T cell responses to
GAD65 is seen as early as 4 weeks of age, parallel to the
onset of insulitis. Also, the proliferative response is ini-
Spleen cell proliferation responses to algal-derived hGAD65 Figure 7
Spleen cell proliferation responses to algal-derived hGAD65. Individual 8-week-old NOD mice were tested for spon-
taneous proliferation of splenocytes to insect cell-derived hGAD65 standard, algal-derived hGAD65 or to the unrelated pro-
tein antigen ovalbumin (OVA). Error bars represent the standard deviation. ** above bars indicates a significant difference from 
OVA and medium alone (p < 0.05).BMC Biotechnology 2008, 8:87 http://www.biomedcentral.com/1472-6750/8/87
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tially confined to limited regions on the GAD65 molecule
and subsequently spreads intramolecularly to different
regions of GAD65 and intermolecularly to other β cell
antigens such as insulin [51]. Kaufman et al. [34] showed
that spleen cells from 8-week-old NOD mice proliferate in
response to GAD peptides. This study shows that NOD
mouse-derived spleen cells proliferate when stimulated
with algal-derived hGAD65, and that the stimulatory
activity of algal-derived hGAD65 is comparable to insect
cell-derived hGAD65 standard. As expected, addition of
an unrelated protein antigen (OVA) had little effect on the
proliferation of NOD mouse-derived spleen cells. The
proliferation of spleen cells from one mouse (mouse #3)
was not significantly altered by the stimulation with either
algal-derived hGAD65 or insect cell-derived hGAD65
standard. This is most likely due to a lower frequency of
GAD reactive T cells within the spleen of this mouse as
compared to other NOD mice. This observation is sup-
ported by Kaufman et al. [34] who examined the in vitro
proliferative responses of spleen cells from individual
NOD mice to GAD stimulation and showed variations in
their proliferative responses to GAD.
The previous work by Ruhlman et al. [18] has showed the
expression of diabetes-associated autoantigen human
proinsulin in plant chloroplasts. In the present work, we
have demonstrated the usefulness of C. reinhardtii chloro-
plasts as another platform for the production of diabetes-
associated autoantigen hGAD65. To our knowledge, this
is the first report on the use of algal chloroplasts for the
production of a human autoantigenic protein. This dem-
onstration opens the way for future use of C. reinhardtii
chloroplasts as bioreactors for the production of other
therapeutic proteins.
Conclusion
Currently there are no efficient expression systems availa-
ble for recombinant production of hGAD65. In the
present study, we have demonstrated that transplastomic
C. reinhardtii is a superior expression platform for the pro-
duction of hGAD65. This is the first report on the use of
C. reinhardtii chloroplasts for the production of a full-
length autoantigenic protein. The ability to produce low-
cost hGAD65 in large quantities will facilitate the devel-
opment of immunoassays useful for screening and moni-
toring large numbers of individuals for susceptibility to
type 1 diabetes, and also for the treatment of patients with
type 1 diabetes.
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